The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) global pandemic significantly impacted CF clinical research within the Cystic Fibrosis Foundation Therapeutics Development Network (CFF TDN). A Research Electronic Data Capture (REDCap) survey was developed and sent to network sites to monitor and understand the impact on research teams, ongoing and anticipated clinical research, and specific clinical and research procedures. Key findings indicated an early impact on participant enrollment, research team stability, and procedures such as spirometry and sputum induction. These trends steadily improved over the months as research activities began to recover across the TDN. While SARS-CoV-2 created a significant challenge it also highlights new opportunities to expand CF research with greater focus on data collection outside of research centers and increased access for remote participation.

中文翻译：

---

SARS-CoV-2 对囊性纤维化基金会治疗开发网络的影响

严重急性呼吸系统综合症冠状病毒 (SARS-CoV-2) 全球大流行对囊性纤维化基金会治疗开发网络 (CFF TDN) 内的囊性纤维化临床研究产生了重大影响。制定了研究电子数据捕获 (REDCap) 调查并将其发送到网络站点，以监测和了解对研究团队、正在进行和预期的临床研究以及具体临床和研究程序的影响。主要发现表明对参与者招募、研究团队稳定性以及肺活量测定和痰诱导等程序的早期影响。随着整个 TDN 的研究活动开始复苏，这些趋势在几个月内稳步改善。虽然 SARS-CoV-2 带来了重大挑战，但它也凸显了扩大 CF 研究的新机遇，更加注重研究中心之外的数据收集，并增加远程参与的机会。